AzTrials
AzTrials

Surgical Procedure, UnspecifiedNETTUNONCT06222021

Hyperlactacidemia in Major Abdominal Surgery and Monocarboxylate Receptors

A study testing Genetic analysis of polymorphism of membrane receptors involved in lactate transport in people with Surgical Procedure, Unspecified and Postoperative Complications, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to identify those situations in which the increase of lactate levels is not clinically relevant since it is associated with altered genetic polymorphism of the genes involved in the membrane proteins acting as carriers for lactate (mainly monocarboxylate transporters, MCTs) patients… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Genetic analysis of polymorphism of membrane receptors involved in lactate transport
Could I receive a placebo?
No, everyone receives an active treatment
How many people
109 participants
Where
1 siteItaly
Study dates
Feb 2024to Oct 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥ 18 years
  • Indication for elective major abdominal surgery

Who cannot join

  • Age <18 years
  • Liver cirrhosis
  • Liver surgery
  • Intraoperative chemotherapy
  • Previous gastric bypass surgery (thiamine deficiency)
  • Severe cardiovascular/respiratory impairment
Show all 10Show fewer
  • Mitochondrial diseases
  • Pheochromocytoma
  • Chronic renal failure ≥ stage III
  • Refusal to sign the informed consent

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • UOC Anestesia delle Chirurgie Generali e dei Trapianti, Fondazione Policlinico Universitario A. Gemelli IRCCS

    Rome, Italy/Lazio, 00168

Other trials in Italy

About this study

Official title: Hyperlactacidemia in Major Abdominal Surgery: Role of Variation in the Monocarboxylate Receptors

The goal of this clinical trial is to identify those situations in which the increase of lactate levels is not clinically relevant since it is associated with altered genetic polymorphism of the genes involved in the membrane proteins acting as carriers for lactate (mainly monocarboxylate transporters, MCTs) patients undergoing major abdominal surgery.

The main questions it aims to answer are:

Read more
  1. Is there a relationship between the lactate levels in the immediate post-operative period and the presence of some lactate receptor polymorphisms?
  2. Can hyperlactacidemia related to lactate receptor polymorphisms affect length of stay in the recovery room and/or in intensive care unit, postoperative hospital stay, postoperative complications? - Which are the risk factors for hyperlactacidemia in the immediate post-operative period in addition to the presence of lactate receptors polymorphisms?

Participants will undergo pre-operative genomic assay testing.

Read the detailed description

Lactic acidosis is traditionally attributed to cellular hypoxia, to an imbalance between the body's demand for oxygen and its availability. Lactate is produced by the muscles, skin, brain, red blood cells and intestine and eliminated by the liver and kidneys. Lactate is produced by the following biochemical reaction: Pyruvate + reduced nicotinamide adenine dinucleotide (NADH) + H+ ↔ Lactate + nicotinamide-adenine dinucleotide (NAD+). Under normal conditions, this reaction produces lactate from pyruvate in a ratio of 10 to 1. Pyruvate comes from glycolysis and is used by mitochondria. When glycolysis is increased or mitochondrial oxidative phosphorylation is blocked, pyruvate accumulates and is converted into lactate generating hyperlactacidemia and acidosis. Normal lactate levels are 0-2 mmol/L. Hyperlactacidemia, usually defined as values above 2.2 mmol/L, is divided into two types: A (associated with hypoxia) and B (related to increased stress-induced aerobic metabolism, mitochondrial diseases and the use of drugs such as metformin and beta2 agonists). The lactate/pyruvate ratio allows us to distinguish the two types of hyperlactacidemia. In hyperlactacidemia type A, this ratio is >10 while in type B it remains constant (L/P=10). In case of liver dysfunction, hyperlactacidemia may be associated with a variable L/P ratio based on the determining cause reduction in lactate clearance. In fact, lactate extraction may depend on the hepatic blood flow, the polymorphism of some genes involved in the lactate transport (mainly MCT1) and the potential of hydrogen (pH) which inhibits gluconeogenesis when lower than 7.10. Since lactic acid is an hydrophilic weak acid, its transport across membranes requires transporters that belong to the transporter family monocarboxylates (MCTs) encoded by the solute carrier family 16 (SLC16) gene family. It has been demonstrated that the MCT1 (rs1049434) T1470A polymorphism is associated with a deficit in the transmembrane transport of lactate: in fact, the T allele is correlated with an approximately 50% reduction in the lactate transport rate compared to the A6 allele. MCT4, which has a very low affinity for pyruvate and a greater affinity for lactate, ensures that pyruvate is converted into lactate before transmembrane transport. Polymorphisms affecting these receptors can influence the different speed of transmembrane lactate flow and therefore correlate with lesser or greater accumulation of serum lactate. Another membrane receptor involved in lactate transport has recently been described: G-coupled protein receptor 81 (GPR81), present in adipocytes. Polymorphisms affecting the gene encoding this receptor could correlate with a different accumulation of lactate. An increase in the level of lactates is often correlated with increased morbidity and mortality in critical situations critical such as sepsis, trauma, major cardiac and abdominal surgery. Measurement of perioperative biomarkers such as lactate is often used in clinical practice as an outcome predictor. However, there are no studies aimed to identify those situations in which the increase of lactates is not clinically relevant since it is associated with altered genetic polymorphism.

The investigators hypothesized that lactate levels at 3 hours after the end of major abdominal surgery will be higher in the patients carrying the T allele versus the A allele for MCT1 gene.

Being tested
Genetic analysis of polymorphism of membrane receptors involved in lactate transport
Medical subject headings
Postoperative Complications, Hyperlactatemia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Genetic analysis of polymorphism of membrane receptors involved in lactate transportGenetic

    The DNA extracted from the blood samples (through extractor MagCore) will then undergo gene sequencing by Sanger sequencing and/or Custom NGS (Next Generation Sequencing) panels and will be used to identify nucleotide variants within genes involved in lactate transport (MCT-1/4, GPR81).

Study groups in NCT06222021
Study groupRoleWhat they receive
Genetic analysis of polymorphisms of membrane receptors involved in lactate transportOtherBefore the start of surgery, after arterial line cannulation, a blood sample will be collected in an ethylenediaminetetraacetic acid (EDTA) test tube for genetic analysis of polymorphisms of membrane receptors involved in lactate transport including transporter family monocarboxylates 1 (MTC1), transporter family monocarboxylates 4 (MTC4) and Gi-coupled protein receptor 81 (GPR81).
Receives: Genetic: Genetic analysis of polymorphism of membrane receptors involved in lactate transport

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Lactate levels

    Lactate levels (mmol/L) in the patients carrying the T allele versus the A allele for MCT1 gene.

    Measured: 3 hours after the end of surgery

Secondary outcomes (6)
  1. Polymorphisms of lactate receptors (presence of MCT4 and GPR8)

    Prevalence of the lactate receptors MCT4 and GPR8 polymorphisms throughout the genetic analysis of a blood sample.

    Measured: Minutes and an average of 30 minutes before the start of surgery

  2. Lactate clearance

    Evaluation of the association between lactate clearance (lactate levels at the end of surgery - lactate levels at 3 hours after the end of surgery)x100/lactate levels at the end of surgery and the presence of lactate receptor polymorphisms (MCT4 and GPR8).

    Measured: 3 hours after the end of surgery

  3. Lactate clearance

    Evaluation of the association between lactate clearance (lactate levels at the end of surgery - lactate levels at 24 hours after the end of surgery)x100/lactate levels at the end of surgery and the presence of lactate receptor polymorphisms (MCT4 and GPR8).

    Measured: 24 hours after the end of surgery

  4. Postoperative recovery

    Length of stay in recovery room (RR) or in intensive care (ICU)

    Measured: Hours (RR) or days (ICU) and average of three hours for RR and one day in ICU

  5. In-hospital stay

    Hospital stay duration

    Measured: Days until discharge, an average of 7 day

  6. Hyperlactacidemia

    Analysis of potential risk factors for hyperlactacidemia (lactate levels >2.2 mmol/L) as well as the presence of lactate receptor polymorphisms including age (years), comorbidities, American Society of Anesthesiologists (ASA) physical status classification system, Body Mass Index (kg/m2), type and duration of surgery (hours), surgical approach (open, laparoscopic, robotic), total of liquids administered (ml), total diuresis (ml), blood losses (ml), intraoperative blood components transfusions (units), blood gas analyses parameters, number of hypotensive episodes during surgery (MAP<65 mmHg) requiring the administration of norepinephrine or its dosage increase.

    Measured: 3 hours after the end of surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jan 2024
  2. Study startFeb 2024 (estimated)
  3. Primary completionAug 2025 (estimated)
  4. Study completionOct 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Model description
Participants will undergo preoperative genomic assay testing
Masking
None (open label)
Enrolment
109 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06222021
Sponsor's protocol ID
5675
Acronym
NETTUNO
Status last verified
Dec 2023
First submitted
2 Jan 2024
Last updated
24 Jan 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Aceto P, Fresta G, Cambise C, Onori ME, Evangelista J, Tulli E, Favitta SF, Sassorossi C, Russo A, Minucci A, Urbani A. MCT1 transporter polymorphism and postoperative hyperlactataemia after major abdominal surgery. Anaesth Crit Care Pain Med. 2026 Oct 7:101932. doi: 10.1016/j.accpm.2026.101932. Online ahead of print.

    PubMed 42843782

Questions about this trial

What is this clinical trial studying?

A study testing Genetic analysis of polymorphism of membrane receptors involved in lactate transport in people with Surgical Procedure, Unspecified and Postoperative Complications, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 24 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Paola Aceto, MD (00390630154507, paola.aceto@policlinicogemelli.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Lactate levels (time frame: 3 hours after the end of surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06222021, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jan 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in